Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bempedoic Acid vs Empagliflozin: Bempedoic Acid has the stronger overall evidence (4.3 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Bempedoic Acid wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Bempedoic Acid and Empagliflozin have evidence — compare verdict strength side-by-side.
180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.
any
Oral tablet (bempedoic acid 180 mg)
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Weeks (full effect by ~12 weeks)
Months to years
Throughout use
Weeks to months
Months to years
Months to years
Weeks to months
Throughout use
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine (2023) · Rct · n=13970
CLEAR Outcomes: ~13,970 statin-intolerant patients randomized to bempedoic acid 180 mg vs placebo
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
The New England journal of medicine (2019) · Rct · n=2230
CLEAR Harmony: 2,230 patients with ASCVD and/or familial hypercholesterolemia on maximally tolerated statins
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
JAMA (2019) · Rct · n=779
CLEAR Wisdom: 779 high-cardiovascular-risk patients on maximally tolerated statins
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Bempedoic Acid has a higher evidence score (4.3/10 vs 4.5/10) and wins in 2 of 3 categories.
Both Bempedoic Acid and Empagliflozin score equally (72) for support heart health.
No known interactions between Bempedoic Acid and Empagliflozin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.